BioWorld

May 25, 2005

Top-Line Lucentis Data Boost Genentech, Hammer Eyetech

Genentech Inc.'s very positive preliminary Lucentis data rippled quickly throughout the industry and sank shares in Eyetech Pharmaceuticals Inc., which sells the already-approved Macugen. (BioWorld Today) Read More

Phenomix's Series B Gets $40M For Diabetes, Arthritis Programs

After Plateau, 'Big Growth Phase' Due For Biotechnology: Vagelos

Isis, Pfizer Collaborating On Eye Disease Antisense Drugs

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 24, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 24, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Illustration of tau accumulating in a neuron cell.

ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

BioWorld

ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...